"Double-Blind Method" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
| Descriptor ID |
D004311
|
| MeSH Number(s) |
E05.318.780.300 E05.581.500.300 N05.715.360.780.320 N06.850.520.445.300
|
| Concept/Terms |
Double-Blind Method- Double-Blind Method
- Double Blind Method
- Double-Blind Methods
- Method, Double-Blind
- Methods, Double-Blind
- Double-Masked Method
- Double Masked Method
- Double-Masked Methods
- Method, Double-Masked
- Methods, Double-Masked
- Double-Masked Study
- Double Masked Study
- Double-Masked Studies
- Studies, Double-Masked
- Study, Double-Masked
- Double-Blind Study
- Double Blind Study
- Double-Blind Studies
- Studies, Double-Blind
- Study, Double-Blind
|
Below are MeSH descriptors whose meaning is more general than "Double-Blind Method".
Below are MeSH descriptors whose meaning is more specific than "Double-Blind Method".
This graph shows the total number of publications written about "Double-Blind Method" by people in this website by year, and whether "Double-Blind Method" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 31 | 31 |
| 1997 | 0 | 34 | 34 |
| 1998 | 0 | 28 | 28 |
| 1999 | 0 | 32 | 32 |
| 2000 | 0 | 30 | 30 |
| 2001 | 0 | 40 | 40 |
| 2002 | 0 | 31 | 31 |
| 2003 | 0 | 41 | 41 |
| 2004 | 0 | 37 | 37 |
| 2005 | 0 | 44 | 44 |
| 2006 | 0 | 46 | 46 |
| 2007 | 0 | 47 | 47 |
| 2008 | 0 | 51 | 51 |
| 2009 | 0 | 49 | 49 |
| 2010 | 0 | 39 | 39 |
| 2011 | 0 | 59 | 59 |
| 2012 | 0 | 52 | 52 |
| 2013 | 0 | 49 | 49 |
| 2014 | 0 | 57 | 57 |
| 2015 | 0 | 48 | 48 |
| 2016 | 0 | 51 | 51 |
| 2017 | 0 | 50 | 50 |
| 2018 | 0 | 53 | 53 |
| 2019 | 0 | 61 | 61 |
| 2020 | 0 | 51 | 51 |
| 2021 | 0 | 50 | 50 |
| 2022 | 0 | 27 | 27 |
| 2023 | 0 | 26 | 26 |
| 2024 | 0 | 41 | 41 |
| 2025 | 0 | 41 | 41 |
To return to the timeline,
click here.
Below are the most recent publications written about "Double-Blind Method" by people in Profiles.
-
Nocturnal Oxygen Therapy for Central Sleep Apnea in Patients with Heart Failure: A Multisite, Double-Blind, Sham-controlled Randomized Clinical Trial (LOFT-HF). Ann Am Thorac Soc. 2025 Dec; 22(12):1951-1960.
-
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study. J Clin Oncol. 2025 Oct 10; 43(29):3209-3220.
-
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. J Am Coll Cardiol. 2025 Oct 07; 86(14):1046-1056.
-
Connectome-based encoding of subjective drug responses to acute oral methamphetamine. Neuropsychopharmacology. 2025 Nov; 50(12):1787-1794.
-
rhPTH(1-84) for hypoparathyroidism: a randomized study of patient-reported outcomes. Eur J Endocrinol. 2025 Jul 31; 193(2):310-319.
-
Methamphetamine-induced adaptation of learning rate dynamics depend on baseline performance. Elife. 2025 Jul 21; 13.
-
Randomized, Proof-of-Concept Trial (RESCUE) of RNS60 as an Adjunct Therapy in Acute Ischemic Stroke. Stroke. 2025 Sep; 56(9):2386-2397.
-
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials. Lancet. 2025 Jul 26; 406(10501):358-375.
-
Safety, Tolerability, and Pharmacokinetics of NRL-1049, a Rho-Associated Kinase Inhibitor, in Healthy Volunteers: A Phase 1, First-in-Human, Single-Ascending Dose, Randomized, Placebo-Controlled Trial. CNS Drugs. 2025 Sep; 39(9):865-877.
-
Effects of methamphetamine on human effort task performance are unrelated to its subjective effects. Psychopharmacology (Berl). 2026 Jan; 243(1):199-209.